Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions

被引:31
作者
Cooper, Wendy A. [1 ]
Kohonen-Corish, Maija R. J. [2 ,3 ]
Zhuang, Liqing [1 ,4 ]
McCaughan, Brian [5 ]
Kennedy, Catherine [6 ]
Screaton, Gavin [7 ]
Sutherland, Robert L. [2 ,3 ]
Lee, C-Soon [4 ,8 ,9 ]
机构
[1] Royal Prince Alfred Hosp, Dept Anat Pathol, Sydney, NSW, Australia
[2] Univ New S Wales, Canc Res Program, Garvan Inst Med Res, Fac Med, Sydney, NSW, Australia
[3] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia
[4] Univ Sydney, Fac Med, Discipline Pathol, Sydney, NSW 2006, Australia
[5] Royal Prince Alfred Hosp, Dept Cardiothorac Surg, Sydney, NSW, Australia
[6] Strathfield Private Hosp, Sydney, NSW, Australia
[7] Univ London Imperial Coll Sci Technol & Med, Royal Postgrad Med Sch, Hammersmith Hosp, London, England
[8] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia
[9] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia
基金
英国医学研究理事会;
关键词
nonsmall cell lung carcinoma; apoptosis; TRAIL receptor; immunohistochemistry; prognosis;
D O I
10.1002/cncr.23528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor, DR5, mediates proapoptotic signals and is implicated in the pathogenesis of many neoplasms including nonsmall-cell lung cancer (NSCLC). METHODS. In this study, immunohistochemical expression of DR5 was examined in 146 cases of stage I and II NSCLC as well as neoplastic precursor lesions and regional lymph node metastases using tissue microarrays. RESULTS. High DR5 expression was observed in 67.1% of primary NSCLC, 55.6% of bronchial squamous carcinoma in situ, 40% of squamous metaplasia, as well as 76.5% of lymph node metastases. In all of these lesions, DR5 expression was significantly higher than in normal bronchial epithelium. Increased expression of DR5 correlated with poorly differentiated tumors and was inversely correlated with bronchioloalveolar carcinomas. There was no correlation with other clinicopathologic variables. A significant association was found between high DR5 expression and reduced overall survival in univariate analysis. Among snickers, high DR5 and tumor stage were independent predictors of reduced disease-free survival in multivariate analysis, however, DR5 was not an independent prognostic marker among the entire cohort of NSCLC. CONCLUSIONS. These findings suggest that DR5 plays a role in the development of early-stage NSCLC and the high levels of DR5 expression suggest that these tumors may be susceptible to novel anticancer agents targeting the DR5 receptor and may improve patient survival, particularly for patients who are smokers.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 43 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Death-receptor activation halts clathrin-dependent endocytosis [J].
Austin, Cary D. ;
Lawrence, David A. ;
Peden, Andrew A. ;
Varfolomeev, Eugene E. ;
Totpal, Klara ;
De Maziere, Ann M. ;
Klumperman, Judith ;
Arnott, David ;
Pham, Victoria ;
Scheller, Richard H. ;
Ashkenazi, Avi .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (27) :10283-10288
[3]   Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects [J].
Baader, E ;
Toloczko, A ;
Fuchs, U ;
Schmid, I ;
Beltinger, C ;
Ehrhardt, H ;
Debatin, KM ;
Jeremias, I .
CANCER RESEARCH, 2005, 65 (17) :7888-7895
[4]   Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis [J].
Bennett, M ;
Macdonald, K ;
Chan, SW ;
Luzio, JP ;
Simari, R ;
Weissberg, P .
SCIENCE, 1998, 282 (5387) :290-293
[5]   Adjuvant chemotherapy for resected non-small cell lung cancer [J].
Booth, Christopher M. ;
Shepherd, Frances A. .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) :180-187
[6]   Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions [J].
Cooper, W. A. ;
Kohonen-Corish, M. R. J. ;
Chan, C. ;
Kwun, S. Y. ;
McCaughan, B. ;
Kennedy, C. ;
Sutherland, R. L. ;
Lee, C-S .
HISTOPATHOLOGY, 2008, 52 (05) :613-622
[7]   Expression of TRAIL and TRAIL receptors in normal and malignant tissues [J].
Daniels, RA ;
Turley, H ;
Kimberley, FC ;
Liu, XS ;
Mongkolsapaya, J ;
Ch'en, P ;
Xu, XN ;
Jin, BQ ;
Pezzella, F ;
Screaton, GR .
CELL RESEARCH, 2005, 15 (06) :430-438
[8]   The clinical trail of TRAIL [J].
Duiker, E. W. ;
Mom, C. H. ;
de Jong, S. ;
Willemse, P. H. B. ;
Gietema, J. A. ;
van der Zee, A. G. J. ;
de Vries, E. G. E. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) :2233-2240
[9]   The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells [J].
Franco, AV ;
Zhang, XD ;
Van Berkel, E ;
Sanders, JE ;
Zhang, XY ;
Thomas, WD ;
Nguyen, T ;
Hersey, P .
JOURNAL OF IMMUNOLOGY, 2001, 166 (09) :5337-5345
[10]   Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression [J].
Fulda, S ;
Meyer, E ;
Debatin, KM .
ONCOGENE, 2002, 21 (15) :2283-2294